reports
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Wim Lewi
- Jacob Mekhael
- Mathijs Geerts Danau
Pharvaris Deucrictibant HAE on-demand phase 3 hits all endpoints
Our initiation thesis is materialising as Pharvaris reported topline phase 3 results for deucrictibant in on-demand HAE, which met the primary and all secondary endpoints, leading the stock to close approx. +22%. Acknowledging the limitations of cross-trial comparison, deucrictibant particularly stands out on time to complete symptom resolution being 12 hours vs. >24 hours with Ekterly, and 83% of attacks resolved with 1 dose vs.
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study ...
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p
- Laura Chico
- Thomas Yip
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
ACET INC.
STTK ADICET BIO INC
TVTX SHATTUCK LABS
VRDN TRAVERE THERAPEUTICS INC
SANA VIRIDIAN THERAPEUTICS INC
PHVS SANA BIOTECHNOLOGY
DAWN PHARVARIS NV
STX DAY ONE BIOPHARMACEUTICALS INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
EWTX GLOBALFOUNDRIES INC
NUVL EDGEWISE THERAPEUTICS INC
ARTV NUVALENT INC
SYRE ARTIVA BIOTHERAPEUTICS INC
RNAC SPYRE THERAPEUTICS INC.
CARTESIAN THERAPEUTICS INC
- Laura Chico
- Thomas Yip
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Mathijs Geerts Danau
Pharvaris 3Q25 update shows all is on-track, eyes are on RAPIDe-3 data...
Pharvaris reported 3Q25 results showing no major surprises and reaffirming previously communicated timelines. The next key milestone is topline results from the phase 3 trial of deucrictibant (B2R antagonist, oral tablet) for on-demand HAE in 4Q25. We are confident in a positive outcome, and see Ekterly's strong early uptake as a key de-risking factor for the commercial potential of orals in the acute HAE market. The company ended the quarter with a cash position of € 329m (YE24: € 281m), provid...
- Wedbush Research
SHOP SHOPIFY INC.
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
CVNA CARVANA CO. CLASS A
ARGX ARGENX ADS
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
BKNG BOOKING HOLDINGS INC.
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
SMCI SUPER MICRO COMPUTER
DASH INC.
ABNB DOORDASH
PHVS AIRBNB INC. CLASS A
XMTR PHARVARIS NV
STX XOMETRY
TTD INC.
GFS SEAGATE TECHNOLOGY HLDGS PLC
CINT THE TRADE DESK
YOU INC.
MLTX GLOBALFOUNDRIES INC
RUM CI&T INC
CART CLEAR SECURE INC
ORKA MOONLAKE IMMUNOTHERAPEUTICS
SERV RUMBLE INC
BBOT MAPLEBEAR INC.
ORUKA THERAPEUTICS INC
SERVE ROBOTICS INC
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- Laura Chico
- Thomas Yip
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Bu...
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release tablet for prophylaxis of HAE attacks, is progressing as planned; topline data anticipated in 2H2026Initiated CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacksData presented at recent medical congresses, incl...
- Mathijs Geerts Danau
Pharvaris New data presented at ACAAI 2025
Pharvaris presented new data at ACAAI 2025. The data highlighted the sustained tolerability and efficacy benefit of deucrictibant in the acute and prophylactic setting. Additionally, results were shared on a new kinin biomarker assay, quality of life outcomes, exposure of the extended release formulation, response to attacks treated with a single dose of deucrictibant, and a comparison to SoC. With this additional data we continue to see Pharvaris as uniquely positioned in the HAE space and look...
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Thibault Leneeuw
- Thomas Couvreur
Data Supporting the Potentially Differentiated Pharvaris Portfolio Pre...
Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral presentationsFinal data from participants in the open-label portion of the CHAPTER-1 study provide further evidence of a well-tolerated safety profile for up to approximately 34 months and an average of 92.4% attack reduction from study baseline with deucrictibant treatmentSix a...
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific...
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of two abstracts for oral presentation and six for poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI)...
- Wedbush Research
CYBR CYBERARK SOFTWARE LTD.
BCRX BIOCRYST PHARMACEUTICALS INC.
MSFT MICROSOFT CORPORATION
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
BDTX BLACK DIAMOND THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
COGT COGENT BIOSCIENCES INC
PHVS PHARVARIS NV
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
ATXS INC
TYRA ASTRIA THERAPEUTICS INC
PEPG TYRA BIOSCIENCES INC
NUVL PEPGEN INC
BBOT NUVALENT INC
BRIDGEBIO ONCOLOGY THERAPEUTICS
- Laura Chico
- Jacob Mekhael
- Mathijs Geerts Danau
Life Sciences Conference 25 Sep 2025
KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.
- Wedbush Research
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.